6. パーキンソン病 [臨床試験数:2,123,薬物数:2,046(DrugBank:324),標的遺伝子数:183,標的パスウェイ数:198

Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03146130
(ClinicalTrials.gov)
July 5, 20183/5/2017Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control DisordersStudy of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's DiseaseImpulse Control Disorder;ParkinsonBiological: Variation of behaviors of Parkinson's diseaseCentre Hospitalier Universitaire, AmiensNULLUnknown status18 YearsN/AAll70Phase 3France
2NCT03104725
(ClinicalTrials.gov)
September 25, 20174/4/2017Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?Parkinson Disease;Cerebrospinal FluidDrug: N-Acetylcysteine;Procedure: Lumbar Puncture;Radiation: FluoroscopyNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 YearsN/AAll6Phase 1United States
3NCT02212678
(ClinicalTrials.gov)
September 20144/8/2014Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseRepeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine capsuleUniversity of MinnesotaParkinson's Disease Society of the United KingdomCompleted18 YearsN/AAll8Phase 2United States
4NCT01470027
(ClinicalTrials.gov)
January 20124/11/2011N-Acetylcysteine for Neuroprotection in Parkinson's DiseaseN-Acetylcysteine for Neuroprotection in Parkinson's DiseaseParkinson DiseaseDrug: N-acetylcysteine;Drug: PlaceboWeill Medical College of Cornell UniversityNational Institute on Aging (NIA)Completed50 Years75 YearsAll50Phase 1/Phase 2United States
5NCT01427517
(ClinicalTrials.gov)
July 201130/8/2011Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseIntravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's DiseaseParkinson's Disease;Gaucher's DiseaseDrug: N-acetylcysteineUniversity of MinnesotaRare Diseases Clinical Research Network;National Center for Advancing Translational Science (NCATS);National Institute of Neurological Disorders and Stroke (NINDS);National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed18 YearsN/AAll9Phase 1United States